Illumina (NASDAQ:ILMN) Reaches New 52-Week Low – What’s Next?

Shares of Illumina, Inc. (NASDAQ:ILMN) hit a new 52-week low during trading on Monday . The company traded as low as $86.70 and last traded at $87.83, with a volume of 307015 shares traded. The stock had previously closed at $88.74.

Analyst Ratings Changes

A number of research firms recently weighed in on ILMN. Citigroup decreased their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research report on Tuesday. UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday. Piper Sandler increased their price target on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Finally, Canaccord Genuity Group lowered their price target on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Stock Up 0.9 %

The stock has a fifty day moving average price of $121.35 and a two-hundred day moving average price of $132.49. The company has a market cap of $13.57 billion, a price-to-earnings ratio of -11.16, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Institutional Investors Weigh In On Illumina

A number of large investors have recently added to or reduced their stakes in ILMN. Stephens Inc. AR grew its holdings in shares of Illumina by 21.5% during the 3rd quarter. Stephens Inc. AR now owns 6,533 shares of the life sciences company’s stock worth $852,000 after purchasing an additional 1,156 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Illumina by 73.3% during the third quarter. Janney Montgomery Scott LLC now owns 6,580 shares of the life sciences company’s stock worth $858,000 after buying an additional 2,783 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Illumina by 74.1% during the third quarter. Robeco Institutional Asset Management B.V. now owns 276,506 shares of the life sciences company’s stock worth $36,059,000 after buying an additional 117,730 shares in the last quarter. National Pension Service increased its holdings in Illumina by 12.4% in the 3rd quarter. National Pension Service now owns 300,661 shares of the life sciences company’s stock valued at $39,209,000 after buying an additional 33,152 shares during the period. Finally, Asset Management One Co. Ltd. raised its position in shares of Illumina by 8.5% in the 3rd quarter. Asset Management One Co. Ltd. now owns 88,743 shares of the life sciences company’s stock valued at $11,573,000 after buying an additional 6,971 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.